These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25111659)

  • 21. The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
    Bancroft EK; Page EC; Brook MN; Pope J; Thomas S; Myhill K; Helfand BT; Talaty P; Ong KR; Douglas E; Cook J; Rosario DJ; Salinas M; Buys SS; Anson J; Davidson R; Longmuir M; Side L; Eccles DM; Tischkowitz M; Taylor A; Cruellas M; Ballestero EP; Cleaver R; Varughese M; Barwell J; LeButt M; Greenhalgh L; Hart R; Azzabi A; Jobson I; Cogley L; Evans DG; Rothwell J; Taylor N; Hogben M; Saya S; ; Eeles RA; Aaronson NK
    BJU Int; 2024 Sep; 134(3):484-500. PubMed ID: 38839570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer.
    Agalliu I; Kwon EM; Zadory D; McIntosh L; Thompson J; Stanford JL; Ostrander EA
    Clin Cancer Res; 2007 Feb; 13(3):839-43. PubMed ID: 17289875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.
    Akbari MR; Wallis CJ; Toi A; Trachtenberg J; Sun P; Narod SA; Nam RK
    Br J Cancer; 2014 Sep; 111(6):1238-40. PubMed ID: 25101567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
    Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
    Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of BRCA1 and BRCA2 in prostate cancer.
    Castro E; Eeles R
    Asian J Androl; 2012 May; 14(3):409-14. PubMed ID: 22522501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
    Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
    BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
    Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
    Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
    Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
    Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of germline MLH1 alterations in familial prostate cancer.
    Fredriksson H; Ikonen T; Autio V; Matikainen MP; Helin HJ; Tammela TL; Koivisto PA; Schleutker J
    Eur J Cancer; 2006 Nov; 42(16):2802-6. PubMed ID: 16963262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
    Brook MN; Ní Raghallaigh H; Govindasami K; Dadaev T; Rageevakumar R; Keating D; Hussain N; Osborne A; Lophatananon A; ; Muir KR; Kote-Jarai Z; Eeles RA
    Eur Urol; 2023 Mar; 83(3):257-266. PubMed ID: 36528478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline BRCA1 mutations increase prostate cancer risk.
    Leongamornlert D; Mahmud N; Tymrakiewicz M; Saunders E; Dadaev T; Castro E; Goh C; Govindasami K; Guy M; O'Brien L; Sawyer E; Hall A; Wilkinson R; Easton D; ; Goldgar D; Eeles R; Kote-Jarai Z
    Br J Cancer; 2012 May; 106(10):1697-701. PubMed ID: 22516946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Clinical and Genetic Analysis of
    Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D
    Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
    Meyer P; Voigtlaender T; Bartram CR; Klaes R
    Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
    Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
    Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
    Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.
    Paulo P; Cardoso M; Brandão A; Pinto P; Falconi A; Pinheiro M; Cerveira N; Silva R; Santos C; Pinto C; Peixoto A; Maia S; Teixeira MR
    Genes Chromosomes Cancer; 2023 Dec; 62(12):710-720. PubMed ID: 37436117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.